Institutional shares held 63.4 Million
264K calls
428K puts
Total value of holdings $539M
$2.25M calls
$3.64M puts
Market Cap $591M
77,121,800 Shares Out.
Institutional ownership 82.24%
# of Institutions 150


Latest Institutional Activity in BLUE

Top Purchases

Q3 2024
Avidity Partners Management LP Shares Held: 1.63M ($12.5M)
Q3 2024
Exodus Point Capital Management, LP Shares Held: 1.3M ($9.93M)
Q3 2024
Lion Point Capital, LP Shares Held: 1.58M ($12.1M)
Q3 2024
Morgan Stanley Shares Held: 969K ($7.42M)
Q3 2024
Goldman Sachs Group Inc Shares Held: 805K ($6.17M)

Top Sells

Q3 2024
Palo Alto Investors LP Shares Held: 604K ($4.63M)
Q3 2024
Millennium Management LLC Shares Held: 1.61M ($12.3M)
Q3 2024
Deutsche Bank Ag\ Shares Held: 92K ($704K)
Q3 2024
Jane Street Group, LLC Shares Held: 259K ($1.99M)
Q3 2024
Aqr Capital Management LLC Shares Held: 678K ($5.2M)

About BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at BLUE

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
592K Shares
From 13 Insiders
Grant, award, or other acquisition 592K shares
Sell / Disposition
74.4K Shares
From 4 Insiders
Open market or private sale 74.4K shares

Track Institutional and Insider Activities on BLUE

Follow bluebird bio, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BLUE shares.

Notify only if

Insider Trading

Get notified when an Bluebird Bio, Inc. insider buys or sells BLUE shares.

Notify only if

News

Receive news related to bluebird bio, Inc.

Track Activities on BLUE